Elise A. Chong

Hospital of the University of Pennsylvania — United States

Medicine · Health Sciences

29h-index6.1kcitations254works5.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(133), Lymphoma Diagnosis and Treatment(123), Chronic Lymphocytic Leukemia Research(59), CNS Lymphoma Diagnosis and Treatment(22), Cutaneous lymphoproliferative disorders research(20)

Publications254 total

Prognostic impact of TP53 alterations in cases of newly diagnosed large B-cell lymphoma
Leukemia·2026
2026 Update on the Management of Diffuse Large B‐Cell Lymphoma
American Journal of Hematology·2026Open Access
Survival after Chimeric Antigen Receptor T-cell Therapy Is Predicted By Fried’s Frailty Phenotype
Transplantation and Cellular Therapy·2026
Long Term Results of Proton Therapy in Adult Infradiaphragmatic Lymphoma
International Journal of Particle Therapy·2026Open Access
Impact of Bispecific Antibody Exposure on CAR T-cell Manufacturing and Toxicity: A Retrospective Analysis
Transplantation and Cellular Therapy·2026
Real-World Evaluation of Health Care Resource Utilization, Clinical Effectiveness, and Safety of Lisocabtagene Maraleucel (liso-cel) and Axicabtagene Ciloleucel (axi-cel) Administered in the Outpatient (OP) Setting for R/R Large B-cell Lymphoma (LBCL)
Transplantation and Cellular Therapy·2026
Cardiovascular outcomes of patients transitioned from ibrutinib to an alternate bruton tyrosine kinase inhibitor for hypertension and/or cardiovascular adverse events
Blood·2025
Outcomes in octo- and nonagenarians treated with mogamulizumab-based regimens for cutaneous T-cell lymphoma
Blood·2025
Frontline experience with second generation covalent Bruton tyrosine kinase inhibitors for mantle cell lymphoma: A single center experience
Blood·2025
Large B-cell lymphoma following CD19-directed CART-cell therapy failure: Impact of CAR construct on disease features and outcomes of subsequent therapies
Blood·2025
Clinical features and outcomes of patients with non-erythrodermic mycosis fungoides with high blood tumor burden
Blood·2025Open Access
Chimeric antigen receptor T-cell therapy in patients with coexisting malignancy and autoimmune disease
Blood·2025Open Access
Firicabtagene autoleucel (firi-cel), a CD22-directed CAR T-cell therapy, for patients with relapsed/refractory large B-cell lymphoma: Results from the phase 2 study (FIRCE-1 Trial)
Blood·2025
Risk factors for failure to complete step-up-dosing of bispecific antibody therapy for B-cell lymphomas
Blood·2025Open Access
Identification and functional characterization of a novel best-in-class anti-CD79b CAR T cell immunotherapy using a multidimensional screening strategy
Blood·2025
Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study
Blood·2025Open Access
A retrospective multi-center review of the safety and efficacy of bispecific T-cell engagers in the management of post-transplant lymphoproliferative disorder – the bite PTLD study
Blood·2025Open Access
Early administration of CD20 x CD3 bispecific antibodies 4-6 weeks after CAR-T infusion for patients with residual or progressive large B cell lymphomas
Blood·2025Open Access
Naive CD4+ at apheresis and disease control at infusion are associated with improved efficacy in second-line CAR T-cells
Blood·2025Open Access
β‑hydroxybutyrate metabolism enhances CAR T cell function via transcriptional and epigenetic reprogramming
Blood·2025Open Access
page 1 of 13Next →

Frequent Co-authors

Stephen J. Schuster(46), Jakub Svoboda(34), Sunita D. Nasta(34), Daniel J. Landsburg(26), Carl H. June(18), Marco Ruella(18), David L. Porter(17), Stefan K. Barta(15), Simon F. Lacey(13), James N. Gerson(12), Bruce L. Levine(11), Noelle V. Frey(11), Anthony R. Mato(10), Hatcher J. Ballard(9), J. Joseph Melenhorst(8), Guido Ghilardi(8), Alfred L. Garfall(8), Anthony R. Mato(7), Raymone Pajarillo(7), Joseph A. Fraietta(7)